O	0	13	Effectiveness
O	14	16	of
O	17	22	early
B-intervention	23	36	physiotherapy
O	37	39	to
O	40	47	prevent
B-condition	48	59	lymphoedema
O	60	65	after
O	66	73	surgery
O	74	77	for
O	78	84	breast
O	85	91	cancer
O	91	92	:
O	93	103	randomised
O	103	104	,
O	105	111	single
O	112	119	blinded
O	119	120	,
O	121	129	clinical
O	130	135	trial
O	135	136	.

O	137	139	To
O	140	149	determine
O	150	153	the
O	154	167	effectiveness
O	168	170	of
O	171	176	early
O	177	190	physiotherapy
O	191	193	in
O	194	202	reducing
O	203	206	the
O	207	211	risk
O	212	214	of
O	215	224	secondary
O	225	236	lymphoedema
O	237	242	after
O	243	250	surgery
O	251	254	for
O	255	261	breast
O	262	268	cancer
O	268	269	.

O	270	280	Randomised
O	280	281	,
O	282	288	single
O	289	296	blinded
O	296	297	,
O	298	306	clinical
O	307	312	trial
O	312	313	.

O	314	324	University
O	325	333	hospital
O	334	336	in
O	337	342	Alcal
O	342	343	รก
O	344	346	de
O	347	354	Henares
O	354	355	,
B-location	356	362	Madrid
I-location	362	363	,
I-location	364	369	Spain
O	369	370	.

B-total-participants	371	374	120
B-eligibility	375	380	women
I-eligibility	381	384	who
I-eligibility	385	388	had
I-eligibility	389	395	breast
I-eligibility	396	403	surgery
I-eligibility	404	413	involving
I-eligibility	414	424	dissection
I-eligibility	425	427	of
I-eligibility	428	436	axillary
I-eligibility	437	442	lymph
O	443	448	nodes
O	449	456	between
O	457	460	May
O	461	465	2005
O	466	469	and
O	470	474	June
O	475	479	2007
O	479	480	.

O	481	484	The
O	485	490	early
O	491	504	physiotherapy
O	505	510	group
O	511	514	was
O	515	522	treated
O	523	525	by
O	526	527	a
O	528	543	physiotherapist
O	544	548	with
O	549	550	a
O	551	564	physiotherapy
O	565	574	programme
O	575	584	including
O	585	591	manual
O	592	597	lymph
O	598	606	drainage
O	606	607	,
O	608	615	massage
O	616	618	of
O	619	623	scar
O	624	630	tissue
O	630	631	,
O	632	635	and
O	636	647	progressive
O	648	654	active
O	655	658	and
O	659	665	action
O	666	674	assisted
O	675	683	shoulder
O	684	693	exercises
O	693	694	.

O	695	699	This
O	700	705	group
O	706	710	also
O	711	719	received
O	720	722	an
O	723	734	educational
O	735	743	strategy
O	743	744	.

O	745	748	The
B-control	749	756	control
I-control	757	762	group
O	763	771	received
O	772	775	the
O	776	787	educational
O	788	796	strategy
O	797	801	only
O	801	802	.

O	803	812	Incidence
O	813	815	of
O	816	826	clinically
O	827	838	significant
O	839	848	secondary
O	849	860	lymphoedema
O	861	862	(
O	862	863	>
O	863	864	2
O	865	867	cm
O	868	876	increase
O	877	879	in
O	880	883	arm
O	884	897	circumference
O	898	906	measured
O	907	909	at
O	910	913	two
O	914	922	adjacent
O	923	929	points
O	930	938	compared
O	939	943	with
O	944	947	the
O	948	951	non
O	951	952	-
O	952	960	affected
O	961	964	arm
O	964	965	)
O	965	966	.

B-total-participants	967	970	116
O	971	976	women
O	977	986	completed
O	987	990	the
O	991	994	one
O	995	999	year
O	1000	1006	follow
O	1006	1007	-
O	1007	1009	up
O	1009	1010	.

O	1011	1013	Of
O	1014	1019	these
O	1019	1020	,
O	1021	1023	18
O	1024	1033	developed
B-outcome	1034	1043	secondary
I-outcome	1044	1055	lymphoedema
O	1056	1057	(
O	1057	1059	16
O	1059	1060	%
O	1060	1061	)
O	1061	1062	:
B-cv-bin-abs	1063	1065	14
O	1066	1068	in
O	1069	1072	the
O	1073	1080	control
O	1081	1086	group
O	1087	1088	(
B-cv-bin-percent	1088	1090	25
I-cv-bin-percent	1090	1091	%
O	1091	1092	)
O	1093	1096	and
B-iv-bin-abs	1097	1101	four
O	1102	1104	in
O	1105	1108	the
O	1109	1121	intervention
O	1122	1127	group
O	1128	1129	(
B-iv-bin-percent	1129	1130	7
I-iv-bin-percent	1130	1131	%
O	1131	1132	)
O	1132	1133	.

O	1134	1137	The
B-outcome	1138	1148	difference
O	1149	1152	was
O	1153	1164	significant
O	1165	1166	(
O	1166	1167	P
O	1167	1168	=
O	1168	1169	0
O	1169	1170	.
O	1170	1172	01
O	1172	1173	)
O	1173	1174	;
O	1175	1179	risk
O	1180	1185	ratio
O	1186	1187	0
O	1187	1188	.
O	1188	1190	28
O	1191	1192	(
O	1192	1194	95
O	1194	1195	%
O	1196	1206	confidence
O	1207	1215	interval
O	1216	1217	0
O	1217	1218	.
O	1218	1220	10
O	1221	1223	to
O	1224	1225	0
O	1225	1226	.
O	1226	1228	79
O	1228	1229	)
O	1229	1230	.

O	1231	1232	A
O	1233	1241	survival
O	1242	1250	analysis
O	1251	1257	showed
O	1258	1259	a
O	1260	1271	significant
O	1272	1282	difference
O	1282	1283	,
O	1284	1288	with
B-outcome	1289	1298	secondary
I-outcome	1299	1310	lymphoedema
I-outcome	1311	1316	being
I-outcome	1317	1326	diagnosed
I-outcome	1327	1331	four
I-outcome	1332	1337	times
I-outcome	1338	1345	earlier
O	1346	1348	in
O	1349	1352	the
O	1353	1360	control
O	1361	1366	group
O	1367	1371	than
O	1372	1374	in
O	1375	1378	the
O	1379	1391	intervention
O	1392	1397	group
O	1398	1399	(
O	1399	1411	intervention
O	1411	1412	/
O	1412	1419	control
O	1419	1420	,
O	1421	1427	hazard
O	1428	1433	ratio
O	1434	1435	0
O	1435	1436	.
O	1436	1438	26
O	1438	1439	,
O	1440	1442	95
O	1442	1443	%
O	1444	1454	confidence
O	1455	1463	interval
O	1464	1465	0
O	1465	1466	.
O	1466	1468	09
O	1469	1471	to
O	1472	1473	0
O	1473	1474	.
O	1474	1476	79
O	1476	1477	)
O	1477	1478	.

O	1479	1484	Early
O	1485	1498	physiotherapy
O	1499	1504	could
O	1505	1507	be
O	1508	1510	an
O	1511	1520	effective
O	1521	1533	intervention
O	1534	1536	in
O	1537	1540	the
O	1541	1551	prevention
O	1552	1554	of
O	1555	1564	secondary
O	1565	1576	lymphoedema
O	1577	1579	in
O	1580	1585	women
O	1586	1589	for
O	1590	1592	at
O	1593	1598	least
O	1599	1602	one
O	1603	1607	year
O	1608	1613	after
O	1614	1621	surgery
O	1622	1625	for
O	1626	1632	breast
O	1633	1639	cancer
O	1640	1649	involving
O	1650	1660	dissection
O	1661	1663	of
O	1664	1672	axillary
O	1673	1678	lymph
O	1679	1684	nodes
O	1684	1685	.

O	1686	1693	Current
O	1694	1704	controlled
O	1705	1711	trials
O	1712	1726	ISRCTN95870846
O	1726	1727	.
